Aclaris Therapeutics (ACRS)
(Real Time Quote from BATS)
$1.16 USD
-0.02 (-1.70%)
Updated May 22, 2024 01:04 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Aclaris Therapeutics, Inc. [ACRS]
Reports for Purchase
Showing records 21 - 28 ( 28 total )
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Broadened Pipeline Becomes Apparent; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
New Boxed Warnings for JAK Inhibitors May Benefit ATI-1777; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Multiple Candidates Advancing; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Positive ATI-1777 Top-Line Phase 2a Data; Cash Replenished; Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-450 Target Indications Broaden; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Managing Autoimmunity by Nuanced Kinase Inhibition; Initiate at Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Managing Autoimmunity by Nuanced Kinase Inhibition; Initiate at Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R